INVICTUSNCT07675018
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Eligibility criteria expanded, about 14 words
- Primary and study completion dates: Sep 21, 2028 to Sep 26, 2028
- Start date changed from estimate of Sep 15, 2026 to Sep 20, 2026
- Secondary endpoints: details revised at 1 of 4 entries
- Site details revised at 7 of 7 sites
- Minor Study description shortened, about 7 words
- Study title shortened, about 3 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
In the experimental arm, empirical parenteral antibiotic therapy will be guided based on the detection of integrons. If integrons detection is positive, a large broad spectrum therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) will be prescribed. If integrons detection is negative, patient will receive a parenteral 3GC (ceftriaxone, cefotaxime, ceftazidime or cefepime). The treatment will be started after the integron detection
In the control arm, the comparative treatment will be an empirical antibiotic therapy with ureidopenicillin and β-lactamase inhibitors combinations (Piperacillin-Tazobactam) or carbapenems (Imipenem, Meropenem) at clinician's discretion. The treatment will be started after the randomization
Diagnostic tests: Detection of integrons
Other: Gold standard
Sites
7 sites in 1 country